Spring Education Exchange (SEE): Beyond CRS and ICANS: CAR T-cell Therapy for CNS Tumors: Nursing Assessment and Management

Spring Education Exchange (SEE): Day 1, Session 2

Presented By:

Christina Baggott PhD, RN, PPCNP-BC, CPON, FAPHON

Ashley Jacobs, RN, BSN, CPN, BMTCN

Courtney Erickson, RN, BSN

Session Details: Day 1: May 14, Session 2: 1:15 PM EST (12:15 PM CST/11:15 AM MST/10:15 AM PST)

Overview of Session: Diffuse midline gliomas (DMG) are aggressive CNS tumors with limited treatment options and poor survival rates. GD2-CART therapy, utilizing genetically engineered T-cells to target GD2 markers on DMG cells, is an emerging approach. Locoregional administration via ventricular reservoirs (e.g., Ommaya) enhances efficacy while reducing systemic toxicity.

This session covers essential nursing assessments and the management of tumor inflammation-associated neurotoxicity (TIAN), categorized as type 1 (mechanical) or type 2 (electrical). Nurses will learn to recognize and manage toxicities ranging from mild to life-threatening, conduct comprehensive evaluations, and provide psychosocial support.

The course also addresses care strategies for both general and intensive care settings, ensuring that nurses are equipped to manage GD2-CART patients throughout their treatment journey.

Learning Outcomes:

• The learner will be able to explain methods to perform thorough a nursing assessment of children with CNS tumors who receive CAR T-cell therapy.
• The learner will be able to incorporate management strategies to ameliorate complications following the administration of CAR T-cell therapy to patients with CNS tumors.

This contains 2 sections:

1. Webinar Recording Link
2. Post-Session Evaluation

Continuing Education Credit 

APHON will provide 1.0 nursing continuing professional development (NCPD) contact hour(s) for the successful completion of this session. Successful completion requires attendance for the entire session and completion of the post-session evaluation. 

Individual Learning Needs Assessment (ILNA) Coding 

This program content has been reviewed by the Oncology Nursing Certification Corporation (ONCC) and is acceptable for recertification points. You may claim 1.0 ILNA in one of the following categories:  

• Care of the Pediatric Hem/Onc Patient 

• Pediatric Hem/Onc Nursing Practice 

• OR Professional Performance. 

Please reach out to the Education Team at education@aphon.org with your name, the email associated with your APHON account, and the above ILNA category you would like to have reflected on your certificate. APHON can update your completion certificate to reflect your choice. 

Spring Education Exchange (SEE) Access 

The SEE session recordings and post-session evaluations will be available for all registered participants until June 19th (11:59 pm EST). 

The Association for Pediatric Hematology Oncology Nurses is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation. This provider is also approved by the California Board of Registered Nursing, Provider Number 14513. 

None of the planners for this activity have relevant financial relationship(s) to disclose with ineligible companies. 

Questions or concerns? Contact education@aphon.org.

The APHON Spring Education Exchange is sponsored by ONCC.